Related Content
- InsightOctober 5, 2023
ERISA Litigation Update
- InsightJuly 19, 2023
ERISA Litigation Update
- AlertApril 19, 2023
A Step Towards Guidance Instead of Regulation by Litigation in the ESOP Space
- InsightApril 11, 2023
ERISA Litigation Update
- AlertApril 11, 2023
A Tale of Two Lawsuits: Federal Court in Texas Suspends FDA Approval of Medication Abortion Drug Mifepristone Nationwide, While Federal Court in Washington Orders FDA to Not Alter Availability of Mifepristone in 17 States and D.C.
- InsightJanuary 5, 2023
ERISA Litigation Update
- AlertJanuary 3, 2023
Department of Labor Finalizes Amendments to Investment Duties Regulation
- AlertDecember 7, 2022
Second Circuit Vacates Certification of Nationwide Class in ERISA Lawsuit
- Press ReleaseNovember 9, 2023
York Capital Management’s Private Equity Group Completes Strategic Growth Investment in Comprehensive Rehab Consultants
- Awards and RankingsAugust 2, 2023
Benchmark Litigation Names Nine Goodwin Partners to 40 & Under Hot List
- In the PressJune 27, 2023
A Step Towards Guidance Instead of Regulation by Litigation in the ESOP Space (Benefits Law Journal)
- Press ReleaseJune 15, 2023
Division of Project Frog Acquired By Industrialized Construction Solutions
- Awards and RankingsJune 13, 2023
The Legal 500 United States 2023 Recognizes Goodwin Lawyers and Practices Nationwide
- Press ReleaseMay 3, 2023
DeMario Carswell Appointed to The ESOP Association’s Advisory Committee on Fiduciary Issues
- Press ReleaseMarch 20, 2023
OncoC4 Announces Strategic Collaboration with BioNTech to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
- Awards and RankingsJanuary 19, 2023
Goodwin Named a Law360 Practice Group of the Year for Fund Formation